Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice

PURPOSE: REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy. METHODS: Radium-223 was admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dizdarevic, Sabina, Petersen, Peter Meidahl, Essler, Markus, Versari, Annibale, Bourre, Jean-Cyril, la Fougère, Christian, Valdagni, Riccardo, Paganelli, Giovanni, Ezziddin, Samer, Kalinovský, Ján, Bayh, Inga, Du, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451709/
https://www.ncbi.nlm.nih.gov/pubmed/30637501
http://dx.doi.org/10.1007/s00259-019-4261-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451709/
https://www.ncbi.nlm.nih.gov/pubmed/30637501
http://dx.doi.org/10.1007/s00259-019-4261-y

Ejemplares similares